MEHMET KURSAD KESKİN

Dr. MEHMET KURSAD KESKİN

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2025
Verified
Book
Open access
PDF file
AMAlper Macif
Alper Macif
ABAhmed Ramiz Baykan
Ahmed Ramiz Baykan
GÇGökhan Çoban
Gökhan Çoban
SYSadik Yavuz
Sadik Yavuz
BBBas Bas
Bas Bas
BBBüşra Başkan
Büşra Başkan
1

5 January 2026 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
FEFatih Eren
Fatih Eren
MGMehmet Refik Göktuğ
Mehmet Refik Göktuğ
DADerya Arı
Derya Arı
GOGulsah Fidan Ozkumur
Gulsah Fidan Ozkumur
EBEda Nur Bulbuller
Eda Nur Bulbuller
MKMurat Kiyici
Murat Kiyici
Background/Aims: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing globally. The Fibrosis-4 (FIB-4) score is a noninvasive biomarker used for assessing potential advanced fibrosis. The study aimed to evaluate the role of the FIB-4 score in predicting postoperative complications and mortality in patients undergoing surgery. Materials and Methods: This multicenter retrospective study included 11 072 patients who underwent surgery under general anesthesia. Demographic and clinical data—including age, gender, comorbidities, FIB-4 scores, American Society of Anesthesiologists classification, postoperative complications, and mortality—were analyzed. Results: A total of 1667 MASLD patients were included. Patients were classified based on FIB-4 scores: 70% (n = 1167) had FIB-4 <1.30, 25.1% (n = 418) had 1.30 < FIB-4 ≤ 2.67, and 4.9% (n = 82) had FIB-4 ≥ 2.67. Due to the limited number of patients with possible advanced fibrosis (FIB-4 ≥ 2.67), propensity score (PS) matching was performed. After PS matching, patients with a high FIB-4 score exhibited a significantly higher rate of postoperative complications (P < .001), and 12-month mortality was elevated (11%), although the difference was not statistically significant (P = .481). Conclusion: A high FIB-4 score may serve as a predictive marker for postoperative complications in patients with MASLD undergoing surgery. Cite this article as: Eren F, Goktug MR, Ari D, et al. Fibrosis-4 score and postoperative outcomes in metabolic dysfunction-associated steatotic liver disease. Turk J Gastroenterol. 2026;37(1):127-135.

14 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
MKMEHMET KURSAD KESKİN
MEHMET KURSAD KESKİN
TTTufan Teker
Tufan Teker
ISIMRAN SAGLIK
IMRAN SAGLIK
NUNesrin Uğraş
Nesrin Uğraş
FEFatih Eren
Fatih Eren
MDMahmut Enver Dolar
Mahmut Enver Dolar
Background: Cytomegalovirus (CMV) reactivation is a clinically important complication in patients with active ulcerative colitis (UC) and has been associated with severe disease activity, treatment refractoriness, and adverse outcomes. The C-reactive protein–albumin–lymphocyte (CALLY) index is a composite biomarker reflecting systemic inflammation, nutritional status, and immune competence. However, its potential role in identifying patients with tissue-confirmed CMV colitis in UC has not been investigated. Methods: This retrospective, single-center cross-sectional study included 82 adults with active ulcerative colitis who underwent tissue evaluation for CMV infection between January 2018 and October 2023. CMV positivity was defined by histopathological and/or immunohistochemical confirmation of CMV infection in colonic biopsy specimens. The CALLY index was calculated as serum albumin × absolute lymphocyte count/C-reactive protein. Receiver operating characteristic (ROC) analysis was performed to evaluate diagnostic performance, and logistic regression analyses were used to identify independent predictors of tissue-confirmed CMV colitis. Results: Eighty-two patients were included, of whom 28 (34.1%) had tissue-confirmed CMV colitis. CMV-positive patients were older and had higher Mayo scores, more extensive disease, lower serum albumin levels, and higher fecal calprotectin concentrations than CMV-negative patients. Although median CALLY index values were numerically higher in CMV-positive patients, the difference did not reach statistical significance (p = 0.136). ROC analysis demonstrated modest discriminative performance for the CALLY index (AUC = 0.601, 95% CI: 0.472–0.722). The optimal CALLY cut-off value of 2838 was derived from the present dataset using the Youden index and yielded a sensitivity of 82.1% and a specificity of 50.0%. In multivariable logistic regression analysis, CALLY ≥ 2838 remained independently associated with tissue-confirmed CMV colitis (OR = 32.09, 95% CI: 3.27–315.39, p = 0.003). Conclusions: The CALLY index demonstrated limited standalone diagnostic performance for identifying CMV colitis in active UC. However, a CALLY value ≥ 2838 was independently associated with tissue-confirmed CMV positivity and may provide complementary information for risk stratification alongside established clinical and inflammatory markers.

29 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMEHMET KURSAD KESKİN
MEHMET KURSAD KESKİN
ACAlper Coskun
Alper Coskun
NUNesrin Ugras
Nesrin Ugras
ECErdem Cubukcu
Erdem Cubukcu
SNSelim Giray Nak
Selim Giray Nak
Background/Objectives: Immune checkpoint inhibitor-related hepatitis (ICI-H) can resemble classical autoimmune hepatitis (AIH), but comparative multidomain data remain limited. We compared their clinical, biochemical, and serological profiles and descriptively summarized histopathological findings. Methods: This single-centre retrospective cohort screened 100 records from January 2018 to October 2023; 79 patients met predefined criteria (40 ICI-H; 39 AIH). ICI-H required an updated RUCAM score of ≥6, whereas AIH required a simplified AIH score of ≥6 and compatible histology. Continuous and categorical variables were assessed using Mann–Whitney U and Fisher’s exact tests with Benjamini–Hochberg correction where applicable; histopathological findings were summarized descriptively because biopsy ascertainment was markedly unequal between groups. Results: Compared with AIH, ICI-H occurred more often in men (65.0% vs. 20.5%) and showed higher AST, ALT, ALP, GGT, INR, CRP, and neutrophil-to-lymphocyte ratio (all q < 0.001), but lower ANA positivity (12.5% vs. 74.4%; q < 0.001). Histopathological observations were limited to the biopsy-assessed subgroup (10 ICI-H; 39 AIH) and are reported descriptively because biopsy ascertainment was markedly unequal and non-random. Conclusions: ICI-H and classical AIH showed different observed clinical, biochemical, and serological profiles; however, these differences should not be interpreted as independent diagnostic discriminators because disease-specific criteria contributed to group assignment. Diagnosis after ICI exposure should integrate exposure timing, exclusion of competing causes, structured causality assessment, serology, and selective histology. Outcome comparisons require standardized longitudinal follow-up.

5 January 2026 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
FEFatih Eren
Fatih Eren
MGMehmet Refik Göktuğ
Mehmet Refik Göktuğ
DADerya Arı
Derya Arı
GOGulsah Fidan Ozkumur
Gulsah Fidan Ozkumur
EBEda Nur Bulbuller
Eda Nur Bulbuller
MKMurat Kiyici
Murat Kiyici
Background/Aims: Despite the widespread use of direct-acting antivirals (DAAs), real-world data on treatment outcomes and predictors of response in hepatitis C virus (HCV) genotypes 2 and 3 remain limited, particularly in countries with heterogeneous patient populations such as Türkiye. This study evaluates the efficacy and safety of direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV) genotype 2 (GT-2) and genotype 3 (GT-3) in Türkiye. Materials and Methods: This cohort is a multicenter, retrospective, and observational study. Data from 267 GT-2 or GT-3 patients treated with a DAA were analyzed. Treatment efficacy was assessed by sustained virological response at 12 weeks after the end of treatment (SVR), and baseline demographic, clinical, and laboratory parameters were evaluated to identify factors associated with treatment response. Results: An overall sustained virological response (SVR) rate of 95.9%, with no significant difference between GTs. The SVR rates were relatively lower in patients with cirrhosis. Prior pegylated interferon and ribavirin reduced SVR rates, particularly in males and patients with cirrhosis. The most common treatments were sofosbuvir-based regimens, which demonstrated comparable efficacy. No significant drug interactions were observed. The most commonly reported adverse events were fatigue and mild anemia, particularly in cirrhotic patients; however, these did not lead to treatment discontinuation. Conclusion: This study supports the efficacy and tolerability of DAA regimens for these HCV GTs, thereby reinforcing their role in HCV eradication. Cite this article as: Eren F, Goktug MR, Ari D, et al. Fibrosis-4 score and postoperative outcomes in metabolic dysfunction associated steatotic liver disease. Turk J Gastroenterol. 2026;37(1):127-135.

25 December 2024 in Akademik Gastroenteroloji Dergisi
Verified
Journal Article
Closed access
PDF file
FEFatih Eren
Fatih Eren
MGMehmet Refik Göktuğ
Mehmet Refik Göktuğ
Selcan CesurSelcan Cesur
Selcan Cesur
MKMEHMET KURSAD KESKİN
MEHMET KURSAD KESKİN
FÇFahri Güven Çakır
Fahri Güven Çakır
MDMahmut Enver Dolar
Mahmut Enver Dolar
Giriş ve Amaç: Ülseratif kolitli hastaların üçte biri akut şiddetli ülseratif kolit ile başvurmakta ve kortikosteroid tedavisi gerekmektedir. Çalışmada kortikosteroide yanıtsız hastalarda infliksimab ve biyobenzerlerinin kurtarma tedavisinde kolektomisiz sağ kalım üzerine etkisi araştırılmıştır. Gereç ve Yöntem: Truelove-Witts aktivite indeksine göre şiddetli kolit kriterlerini karşılayan ve intravenöz kortikosteroid tedavisine yanıtsız olması nedeniyle infliksimab kurtarma tedavisi verilen 48 hasta retrospektif olarak değerlendirildi. Klinik kötüleşme, yeni tedaviye geçilme gerekliliği ve kolektomi ihtiyacı progresyon olarak tanımlandı. Kısa süreli (3 ay) ve uzun süreli (12 ay) kolektomisiz sağ kalım primer sonlanım olarak kabul edildi. Ayrıca orijinal ve biyobenzer infliksimab etkinlik açısından karşılaştırıldı. Bulgular: 14 hastaya orijinal infliksimab, 34 hastaya biyobenzer infliksimab tedavisi verilmişti. Kısa ve uzun süreli sonlanımda hiçbir hastada kolektomi ihtiyacı saptanmadı. İki yıl ve üzerinde biyobenzer infliksimab tedavisi alan iki hastaya kolektomi uygulanmış olduğu saptandı. Progresyon varlığına göre sağ kalım sürelerinin istatistiksel olarak farklılık gösterdiği belirlendi (p < 0.001). Genel sağ kalım süresinin ise farklılık göstermediği saptandı (p > 0.05). Sonuç: Kortikosteroide refrakter şiddetli ülseratif kolitli hastalarda kolektomisiz sağ kalım için hem orijinal hem de biyobenzer infliksimab etkili bulundu.